Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

華潤醫藥集團有限公司
China Resources Pharmaceutical Group Limited
(Incorporated in Hong Kong with limited liability)
(Stock Code: 3320)

ANNOUNCEMENT

UNAUDITED FINANCIAL RESULTS OF CR DOUBLE-CRANE FOR THE SIX MONTHS ENDED 30 JUNE 2025

On 22 August 2025, CR Double-Crane released its interim report for the six months ended 30 June 2025.

China Resources Double-Crane Pharmaceutical Co., Ltd.(華潤雙鶴藥業股份有限公司)("**CR Double-Crane**") is a company incorporated in the People's Republic of China. The shares of CR Double-Crane are listed on the Shanghai Stock Exchange. As of the date of this announcement, CR Double-Crane is indirectly owned as to 60.24% by China Resources Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") and is a subsidiary of the Company.

On 22 August 2025, CR Double-Crane released its interim report for the six months ended 30 June 2025 (the "**CR Double-Crane Unaudited Financials**"). Set out below is the key financial information of the CR Double-Crane Unaudited Financials:

	As of 30 June 2025 *(RMB)* (unaudited)	**As of 31 December 2024** *(RMB)* (audited)	**Increase** *(%)*
Total assets	**16,741,002,778.93**	16,685,995,679.77	0.33
Net assets attributable to shareholders of the listed company	**11,041,026,876.74**	10,407,864,932.00	6.08

	For the six months ended 30 June		
	2025 *(RMB)* (unaudited)	**2024** *(RMB)* (unaudited)	**Increase/ Decrease** *(%)*
Revenue	**5,741,509,806.80**	5,929,090,777.20	-3.16
Net profit attributable to the shareholders of the listed company	**975,491,614.76**	1,046,534,624.68	-6.79
Net profit attributable to the shareholders of the listed company (exclude extraordinary gains or losses)	**932,772,371.82**	921,580,597.17	1.21
Net cash flow from operating activities	**662,173,851.53**	935,743,889.88	-29.24
Basic earnings per share *(RMB/share)*	**0.9480**	1.0199	-7.05
Diluted earnings per share *(RMB/share)*	**0.9480**	1.0199	-7.05
Weighted average return on net asset *(%)*	**8.99%**	9.38%	-0.39 percentage points

As determined by the board of directors of CR Double-Crane, CR Double-Crane proposed to distribute a cash dividend of RMB1 (inclusive of tax) for every 10 shares to all CR Double-Crane's shareholders based on the total share capital of CR Double-Crane on the date of equity distribution registration. Such proposal shall be submitted for shareholders' approval at CR Double-Crane's extraordinary general meeting.

The CR Double-Crane Unaudited Financials have been prepared in accordance with the PRC Generally Accepted Accounting Principles, have not been reviewed or audited by the Company's auditors, and may require adjustment during the course of auditing. The financial information is limited to CR Double-Crane only and does not represent or provide a complete view of the operational or financial status of the Group. **Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.**

For further details of the CR Double-Crane Unaudited Financials, please refer to the interim report for the six months ended 30 June 2025 published by CR Double-Crane on the website of the Shanghai Stock Exchange (www.sse.com.cn).

By order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 22 August 2025

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director; Mr. Tao Ran and Mdm. Deng Rong as executive Directors; Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive Directors.